LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

Summary Background Tumor-associated macrophages (TAMs) promote tumor growth, metastasis, and therapeutic resistance via colony-stimulating factor-1 (CSF-1), acting through CSF-1 receptor (CSF-1R) signaling. This phase 1 study determined the safety, tolerability, pharmacokinetics-pharmacodynamics, im...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Investigational new drugs 2021-08, Vol.39 (4), p.1057-1071
Hauptverfasser: Dowlati, Afshin, Harvey, R. Donald, Carvajal, Richard D., Hamid, Omid, Klempner, Samuel J., Kauh, John Sae Wook, Peterson, Daniel A., Yu, Danni, Chapman, Sonya C., Szpurka, Anna M., Carlsen, Michelle, Quinlan, Tonya, Wesolowski, Robert
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!